Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02674295 · ClinicalTrials.gov registry record · Phase 1
A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02674295 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 8 participants.
The verdict
NCT02674295, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the metabolic disposition of radiolabeled esketamine administered by the oral and intravenous routes in healthy male participants.
Interventions
- DRUG Esketamine 50 mg
- DRUG Esketamine 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02674295
The ClinicalTrials.gov registry entry for NCT02674295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Esketamine 50 mg is the first listed.
NCT02674295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02674295 about?
NCT02674295 is a clinical study titled "A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants". The purpose of this study is to determine the metabolic disposition of radiolabeled esketamine administered by the oral and intravenous routes in healthy male participants.
What is the current status of trial NCT02674295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2016-03. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02674295?
The interventions under investigation include: Esketamine 50 mg (DRUG), Esketamine 20 mg (DRUG).
Who is sponsoring clinical trial NCT02674295?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.